key: cord-0943231-lkmas1pu authors: Huang, Rui; Zhu, Li; Wang, Jian; Xue, Leyang; Liu, Longgen; Yan, Xuebing; Huang, Songping; Li, Yang; Yan, Xiaomin; Zhang, Biao; Xu, Tianmin; Li, Chunyang; Ji, Fang; Ming, Fang; Zhao, Yun; Cheng, Juan; Wang, Yinling; Zhao, Haiyan; Hong, Shuqin; Chen, Kang; Zhao, Xiang‐an; Zou, Lei; Sang, Dawen; Shao, Huaping; Guan, Xinying; Chen, Xiaobing; Chen, Yuxin; Wei, Jie; Zhu, Chuanwu; Wu, Chao title: Clinical features of COVID‐19 patients with non‐alcoholic fatty liver disease date: 2020-08-06 journal: Hepatol Commun DOI: 10.1002/hep4.1592 sha: 46b551aeb41464790e666d57e04187f96bf00568 doc_id: 943231 cord_uid: lkmas1pu BACKGROUND AND AIMS: Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in COVID‐19 patients with chronic liver diseases. We described the clinical features in COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). METHODS: Confirmed COVID‐19 patients from hospitals in 10 cities of Jiangsu province, China were retrospectively included between January 18, 2020, and February 26, 2020. Hepatic Steatosis Index (HSI) was used to defined NAFLD. RESULTS: A total of 280 COVID‐19 patients were enrolled. Eighty‐six (30.7%) of 280 COVID‐19 patients were diagnosed as NAFLD by HSI. 100 (35.7%) patients presented abnormal liver function on admission. The median ALT levels (34.5 U/L vs. 23.0 U/L, P<0.001) and the proportion of elevated ALT (>40 U/L) (40.7% vs. 10.8%, P<0.001) were significantly higher in patients with NAFLD than in patients without NAFLD on admission. The proportion of elevated ALT in patients with NAFLD was also significantly higher than patients without NAFLD (65.1% vs. 38.7%, P<0.001) during hospitalization. Multivariate analysis showed that age over 50 years (odds ratio [OR] 2.077, 95% confidence interval [CI] 1.183‐3.648, P=0.011), and concurrent NAFLD (OR 2.956, 95% CI 1.526‐5.726, P=0.001) were independent risk factors of ALT elevation in COVID‐19 patients, while the atomized inhalation of interferon α‐2b (OR 0.402, 95%CI 0.236‐0.683, P=0.001) was associated with the reduced risk of ALT elevation during hospitalization. No patient developed liver failure or death during hospitalization. The complications and clinical outcomes were comparable between COVID‐19 patients with and without NAFLD. CONCLUSIONS: NAFLD patients are more likely to develop liver injury when infected by COVID‐19. However, no patient developed severe liver‐related complications during hospitalization. Patients with the following comorbidities were excluded: viral hepatitis (defined by positive 148 serum positive serum hepatitis B surface antigen and/or hepatitis C antibody and/or had a 149 known history of chronic hepatitis B or chronic hepatitis C), significant alcohol 150 consumption (defined by > 30 grams per day in men and >20 g/d in women), autoimmune 151 hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, or any other chronic liver 152 diseases. Our study was approved by the Ethics Committee of these hospitals, with a 153 waiver of informed consent. Abnormal liver function was defined as any parameter (ALT, AST, GGT, ALP or Tbil) 161 higher than the upper limit of normal. For the definitions of NAFLD, previously mentioned method was utilized. We defined 164 NAFLD using the Hepatic Steatosis Index (HSI) in the absence of other causes of CLD. (12) 165 This index has been validated previously and used in several studies. ( United States). Continuous data were presented medians (interquartile range (IQR)). Categorical data were shown as the counts and percentages. Continuous variables 174 between two groups were analyzed using two-sample t tests or Mann-Whitney U as 175 appropriate, while categorical variables were analyzed by Chi-square tests or Fisher's 176 exact tests. Logistic regression was performed to select independent risk factors of 177 elevated ALT (>40 U/L). Variables having P values <0.05 in the univariate analysis were 178 used for a multivariate input logistic regression analysis. P<0.05 was considered to be 179 statistical significant. This article is protected by copyright. All rights reserved 201 non-NAFLD patients. However, the age and gender were comparable between two 202 groups. There were also no significant differences in symptoms, comorbidities and 203 exposure history between two groups. (Table 1) 204 Laboratory and radiology examination 205 On admission, the baseline white blood cells (WBC) and lymphocyte levels were 4.9 (IQR 206 3.9-6.2) and 1.2 (IQR 0.9-1.6), respectively. The proportions of leukopenia and (Table 3) . Treatment and clinical prognosis 258 Atomized inhalation of interferon α-2b, lopinavir/ritonavir, and arbidol were the most 259 commonly used antiviral drugs in our study, which account for 57.1%, 72.5%, and 49.3% 260 of patients, respectively (Table 5) . 73.6% patients received empirical antibiotic treatment. This article is protected by copyright. All rights reserved 312 The risk factors of liver injury in COVID-19 were analyzed. Age over 50 years was a risk 313 factor of ALT elevation. Thus, more attention should be paid to elderly patients. In our 314 study, atomized inhalation of interferon α-2b was found to be related with the reduced risk 315 of ALT >40 U/L. The possible interpretation may be that atomized inhalation of interferon 316 α-2b may suppress the SARS-CoV-2 and reduce the liver impairment caused by the virus. However, further studies are needed to confirm our hypothesis. In our study, only 7.9% patients developed respiratory failure and 1.4% patients 319 progressed to ARDS. 6.4% patients were transferred to the ICU during hospitalization. No In general, the prevalence of DM is higher in NAFLD patients than non-NAFLD 333 patients. (24) The incidence of DM in NAFLD patients (11.6%) was higher than non-NAFLD 334 patients (5.7%). However, there was no significant difference of incidence of DM between 335 these two groups (P=0.081). The possible reason may be explained by the relative small 336 sample size with only 21 patients (7.5%) having DM in our study. In our study, FBG levels This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved /publications-detail/clinical-managementof-severe-acute-respiratory-infection-w 392 hen-novelcoronavirus-(ncov)-infection-is-suspected) World Health Organization. Laboratory diagnostics for novel coronavirus Hepatic Steatosis Index: A Simple 397 Associated With Non-Alcoholic Fatty Liver Disease Among Adults in the United States Race/ethnicity-based Temporal Changes in Prevalence of NAFLD-related Advanced 404 Fibrosis in the United States Are Associated With Non-Alcoholic Fatty Liver Disease Among 407 Adults in the United States Performance and Limitations of Steatosis Biomarkers in Patients With Nonalcoholic 410 Fatty Liver Disease Guidelines of Prevention and Treatment of Nonalcoholic 412 The Epidemiology of NAFLD in 414 Mainland China With Analysis by Adjusted Gross Regional Domestic Product: A Accepted Article This article is protected by copyright COVID-19-Related Liver Damage Specific ACE2 expression in 419 cholangiocytes may cause liver damage after 2019-nCoV infection Fatty Liver Disease in Brazil. Clinical and Histological Profile Non-alcoholic fatty liver diseases 425 in patients with COVID-19: A retrospective study Metabolic associated 428 fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic 429 patients Clinical availability of nonalcoholic fatty liver 431 disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year 432 prospective cohort study Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to 435 Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart 436 This article is protected by copyright. All rights reserved